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Pulmonary hypertension caused by pulmonary
venous hypertension
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Cardiac Critical Care, and the Pulmonary Hypertension Program, Boston Children’s Hospital, Boston, Massachusetts, USA
Abstract: The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordi-
narily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The
reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remod-
eling (especially medial hypertrophy and intimal hyperplasia) account for increased PVR when present.
The mechanisms involved in vasoconstriction and remodeling are not clearly deﬁned, but increased wall
stress, especially in small pulmonary arteries, presumably plays an important role. Myogenic contraction
may account for increased vascular tone and also indirectly stimulate remodeling of the vessel wall. In-
creased wall stress may also directly cause smooth muscle growth, migration, and intimal hyperplasia.
Even long-standing and severe pulmonary hypertension (PH) usually abates with elimination of PVH, but
PVH-PH is an important clinical problem, especially because PVH due to left ventricular noncompliance
lacks deﬁnitive therapy. The role of targeted PH therapy in patients with PVH-PH is unclear at this time.
Most prospective studies indicate that these medications are not helpful or worse, but there is ample reason
to think that a subset of patients with PVH-PH may beneﬁt from phosphodiesterase inhibitors or other
agents. A different approach to evaluating possible pharmacologic therapy for PVH-PH may be required to
better deﬁne its possible utility.
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As a perfect example of how clinical imperative can drive
basic physiological investigation, studies of the effect of
pulmonary venous hypertension (PVH) on the lung’s cir-
culation were in full swing by the very early 1950s,
1 close
on the heels of the development of surgical relief of mi-
tral valve stenosis. Cardiac catheterization of patients with
mitral valve disease has characterized the physiology of
PVH, and histological investigations demonstrated the
microvascular changes provoked by PVH. Just as impor-
tant, the effect of relief of left atrial (LA) hypertension on
the circulation has been extensively reported, usually for
patients who have had mitral valve intervention. We have
learned that the circulatory alterations provoked by PVH
share some characteristics with other forms of pulmonary
hypertension (PH), such as the idiopathic variety, PH due
to chronic alveolar hypoxia, and PH secondary to congeni-
tal cardiac shunting lesions. For example, acute “reactivity”
to vasodilators may be observed, and there is overlap in the
microarchitectural abnormalities seen. On the other hand,
the “natural history” of PVH-PH is very different than that
of the idiopathic variety or that seen with shunting defects:
in the former (as demonstrated with mitral valve disease),
PH is likely to largely or completely resolve if PVH is
relieved, even with long-standing and severely increased
pulmonary vascular resistance (PVR),
2,3 while in the latter
two, PH is more likely to inexorably increase. PVH-PH is
therefore one of the very few “models” of increased PVR in
which removal of the stimulus is often possible, which is
followed by substantial reduction of PVR. (PH caused by
chronic alveolar hypoxia shares this quality, but the vascu-
lar pathology and elevation of PVR are usually much less
severe).
4-7
This review will discuss (1) anatomic and physiologic
abnormalities that cause PVH; (2) how PVH impacts the
Address correspondence to Dr. Thomas J. Kulik, Pulmonary Hypertension Program, Boston Children’s Hospital, 300 Longwood Avenue, Boston,
MA 02115, USA. E-mail: thomas.kulik@cardio.chboston.org.
Submitted November 12, 2013; Accepted April 16, 2014; Electronically published October 13, 2014.
© 2014 by the Pulmonary Vascular Research Institute. All rights reserved. 2045-8932/2014/0404-0005. $15.00.pulmonarymicrovasculararchitectureandphysiology,with
emphasis on its effect on PVR; (3) the effect of reduction of
pulmonaryvenous pressureonPVR;(4) mechanical forces,
especially increased wall stress, as the putative proximate
cause of increased PVR with PVH; and (5) issues related to
evaluating pharmacologic therapy aimed at reducing PVH-
PH. The effect of PVH on lung water is an important but
somewhat distinct issue and is not explored. Clinical pre-
sentation and diagnostic evaluation are not discussed, nor
are speciﬁc therapeutic recommendations offered.
CAUSES OF PVH
Multiple abnormalities increase pulmonary venous pres-
sure. One can, and probably should, separate the causes
of PVH into two types: (i) those involving increased pres-
sure in the left atrium or extrapulmonary pulmonary
veins are referred to as category 1 (corresponding to Dana
Point group 2, PH due to left heart disease), and (ii) con-
ditions with primary stenosis/occlusion of intrapulmo-
nary veins (but with normal LA pressure), referred to as
category 2 in this review. The Dana Point classiﬁcation
does not speciﬁcally accommodate stenosis of the large
intrapulmonary veins, although pulmonary veno-occlusive
disease is classiﬁed as group 1. Both categories share cer-
tain characteristics. For example, PH of variable magni-
tude and some tendency for pulmonary vasodilators to
provoke pulmonary edema are seen with both LA hyper-
tension and pulmonary veno-occlusive disease.
8-11 On the
other hand, the biology of pathological vascular remodel-
ing originating within the lung (rather than in response to
increased LA or proximal pulmonary venous pressure)
12
must be in some ways different from that seen with cate-
gory 1 PVH. Discussion in this review refers to observa-
tions made in and pertinent to category 1 PVH.
Category 1: anatomic and physiologic abnormalities
which increase LA or extrapulmonary vein pressure
There are many varieties of these abnormalities, the
most important of which include the following:
i) Anomalously connected pulmonary veins and
cor triatriatum.
13,14 Anomalous connection of
the pulmonary veins (to the right atrium, sys-
temic or hepatic veins, or the coronary sinus) can
occur with or without obstruction to egress of
blood from the veins. In the former, pulmonary
vein pressure is usually elevated, and PH can be
severeafterbirth.
ii)Congenital and acquired structural abnormali-
ties of the mitral valve, including supravalvar
mitral ring.
15-18 Rheumatic mitral valve disease
is the most common of these abnormalities.
iii) Narrowing of the extrapulmonary veins. This
can be congenital, develop for occult reasons
postnatally,
19 or develop after surgery to correct
anomalously connected veins.
20
iv) Left ventricular (LV) noncompliance. LV dia-
stolic dysfunction is seen in multiple settings:
with dilated, hypertrophic or restrictive cardio-
myopathy; structural lesions causing increased
LV pressure or volume load (e.g., aortic steno-
sis); systemic hypertension; in patients with
congenital cardiac defects and a small LV.
21,22
Heart failure and preserved ejection fraction
and heart failure with reduced ejection fraction
are the most frequent causes of PH due to re-
duced LV compliance.
21
Category 2: pulmonary venous stenosis/obstruction
within the lung parenchyma
i) Acquired stenosis or atresia of the intrapulmonary
veins. This occurs in several settings: idiopathic,
in prematurely born infants with bronchopulmo-
nary dysplasia, after surgical repair of anoma-
lously connected pulmonary veins (includingthose
not obstructed at time of repair), in patients with
congenital heart defects without anomalous pul-
monary vein connection, and under other circum-
stances.
19,20,23-25 It seems unlikely that a single ste-
notic pulmonary vein can cause signiﬁcant PH,
26
although manifest obstruction of one or more pul-
monary veins in one lung can exist with occult ob-
struction of small veins in the contralateral lung,
and additional obstructed veins can develop over
time.
27
ii) Pulmonaryveno-occlusivedisease.Inthisraredis-
ease, there is stenosis and occlusion of venules
and small veins and generally severe and progres-
sive PH.
9
T H EI M P A C TO FP V HO NP V R :S T R U C T U R E ,
PHYSIOLOGY, AND REVERSIBILITY
Pulmonary arterial pressure (PAP) is increased with PVH,
often only due to passive transmission of pulmonary ve-
nous pressure (i.e., PVR is unchanged), although PVR in
this setting is highly variable and is frequently much in-
creased (see the upper right panel of Fig. 1 in this article
and Fig. 2 in Kulik et al.
31). In 5 reports of adults under-
going intervention for mitral valve disease (n = 96 pa-
582 | Pulmonary venous hypertension and PH Kuliktients), mean PAP ranged from 25 to 104 mmHg (mean
 standard deviation, 47  12 mmHg), and 41% had
mean PAP ≥50 mmHg.
32-36 Most patients had little or
no increase in PVR, but 4 large series reported 23%–
29% of adults with mitral valve disease to have PVR ≥5
units.
28,37-39 Data from Guazzi and Borlaug
37 indicate
roughly the same for patients with LV noncompliance,
and variability in PVR is also the case for children with
pulmonary vein obstruction (personal observations), indi-
cating that variability in PVR with PVH is a general phe-
nomenon and not limited to mitral valve disease. The
fact that many patients have normal PVR may be partly
due to passive distention of pulmonary resistance vessels
due to pulmonary venous hypertension.
41,42
Considerable note has been made of PH “out of propor-
tion” to the magnitude of LA pressure (i.e., a transpulmo-
nary gradient >12 mmHg).
40,43 Some observers even sug-
gest that this disproportionate increase in PAP may be due
to factors independent of the PVH.
44 Although this notion
may be useful in thinking about which patients might most
Figure 1. How pulmonary venous hypertension (PVH) causes increased pulmonary vascular resistance (PVR). Increased intravascu-
lar pressure increases wall stress in resistance-level pulmonary arteries (PAs), increasing stretch/tension in medial smooth muscle
cells (SMCs). This stimulates mechanoreceptors in these cells, causing vasoconstriction, which reversibly increases PVR and also
provokes structural changes. The latter may result from shared pathways for smooth muscle contraction and growth and/or re-
duction in blood ﬂow in very small end and branch PAs. Increased stretch/tension may also directly (independent of vasoconstriction)
stimulate medial hypertrophy and intimal hyperplasia. In the upper right panel, pulmonary capillary wedge pressure (PCWP) is
plotted against PVR (pulmonary vascular resistance) in 114 adult patients with mitral stenosis (data from Wood et al.
28); PVR ranges
from normal, despite very high left atrial pressure, to markedly elevated, despite only a modest increase in pulmonary venous
pressure. The upper left panel shows the effect of inhaled nitric oxide (iNO) on PVR in 13 children with left atrial hypertension (data
from Atz et al.
29), demonstrating that a component of increased PVR with PVH is often acutely reversible. BL: baseline, before iNO.
The lower right panel shows the relative rate of protein synthesis in the media of rabbit PA strips in tissue culture was measured at
wall stresses equivalent to various mean PA pressures using quantitative autoradiography. Protein synthesis increased with wall stress
in an endothelium-independent manner; hydrostatic pressure did not alter protein synthesis. Adapted from Kolpakov et al.
30 DE:
endothelium removed; EN: endothelium present; PS: hydrostatic pressure.
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seems likely that “out of proportion” is actually a reﬂection
of garden variety biological variability. Indeed, it has been
long appreciated
45 that the lung’s circulation demonstrates
considerable variability in its response to multiple stimuli,
including acute and chronic hypoxia,
46,47 and chronic eleva-
tion of ﬂow and pressure due to congenital shunting le-
sions
45 (Fig. 2). That is not to say that there is no cellular or
molecular basis for this marked variability, just that it is not
limited to the response of the pulmonary circulation to
PVH. Comparing the genetic, proteomic, and metabolic
characteristics of patients with striking elevation in PVR
with PVH with those of patients evincing normal PVR de-
spite severe PVH may someday yield insights into the mech-
anisms involved.
Increased PVR with PVH is due to pathological
remodeling and active vasoconstriction
Pathological remodeling. With mitral stenosis, in small
pulmonary arteries (PAs) there is distal extension of
smooth muscle, medial hypertrophy and ﬁbrosis, longi-
tudinal bundles of smooth muscle in the media, and
adventitial thickening.
48 Donald Heath,
49 in an early analy-
sis of lung tissue from mostly older adults with mitral ste-
nosis, found no more intimal thickening than in control
subjects, but many subsequent reports have described sub-
stantial intimal thickening and even ﬁbrosis, including in
young patients.
50-54 (Two observers in the mid-1950s even
averred that mitral valvotomy was unlikely to be of beneﬁt
given the extent of the arterial intimal changes,
55 ad e m o n -
stration of how tenuous the link can be between histology,
physiology, and prediction in the pulmonary circulation.)
Higher-grade lesions (e.g., dilatation and plexiform) are but
very uncommonly described,
51,56 and some observers do
not believe that they are a feature of PVH-PH.
48 The small
veins often (but not always) have thickened and ﬁbrotic
media and may be arterialized (i.e., elastin ﬁbers are con-
densed into internal and elastic laminae). There may also
be intimal ﬁbrosis and longitudinal bundles of smooth
muscle cells (SMCs). The capillaries are engorged, with
thickened basement membranes. The lymphatics are di-
lated and thicker than normal.
57
Wagenvoort and Wagenvoort
57 found littlecorrelation be-
tween pulmonary hemodynamics and histological changes,
although others have. I am aware of no information regard-
ingthetimecourseofremodeling,although,asnotedabove,
intimal lesions have been described in young children, and
pathological remodeling of PA and venous vessels occurs in
utero with obstructedpulmonary venous return.
58
Vasoconstriction. That PVH can cause vasoconstriction
is manifest by an acute decrease in PAP/PVR with vasodi-
lators (intravenous acetylcholine, hexamethonium, pris-
colene, and inhaled NO; see upper left panel in Fig. 1). The
response to these agents is variable, and not all patients
s h o wv a s o d i l a t i o n ,b u tad e c r e a s eo fa p p r o x i m a t e l y4 0 %i n
PAP/PVR is typical.
28,59-61 Vasoconstriction is also inferred
from the fact that PVR often decreases within hours of
mitral valve intervention, followed by a further decrease
over months (the latter presumably reﬂecting remodeling
of pulmonary vessels).
34-36,62 In 4 series of balloon mitral
valvuloplasty (total, 114 patients), the mean ( standard
deviation) percentage decrease in PVR immediately after
the procedure was 24%  8%, and several months later the
PVR was 51%  9% lower than at baseline.
34-36,63 Ia m
aware of nopublished information relating “reactivity” with
vasodilators with change in PVR after mitral valve interven-
tion.
Evolution and resolution of PH
As previously noted, despite having PH for many years,
adults and older children
52,54,56,64 with mitral valve dis-
Figure 2. Change in pulmonary vascular resistance (PVR) after
mitral valve intervention to effect relief of mitral stenosis/regurgi-
tation (circles; n = 61 patients) or closure of ventricular septal de-
fect (VSD; dots, n = 110 patients). Nearly all patients with mitral
valve disease had a large decrease in PVR after relief of left atrial
hypertension. Conversely, for patients with a VSD, the response
was quite variable, and many had unchanged or increased PVR
after repair. Adapted from Kulik.
3 MVI: mitral valve intervention.
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(albeit not invariably) show a substantial decrease or even
normalization of PVR (Fig. 2); even patients with mean
PAP >50 mmHg generally show a large reduction in PAP
and PVR.
28,63,65,66 Most available hemodynamic data are
for ≤1 year of follow-up, but one large series demonstrated
that the reduction in PVR lasts at least several years.
67
Reliable reduction of PVR with mitral valve replace-
ment or repair probably also occurs in the ﬁrst few years
of life,
31,54,56 although the available data are limited and
far from deﬁnitive. (Published long-term follow-up data
for patients with signiﬁcant and isolated [i.e., without
left-to-right shunting] PVH and PH at birth are scant,
which is surely a reﬂection of the tendency of these pa-
tients to die early absent relief of the PVH.) This is note-
worthy, because it is possible that long-standing PH
since birth may be much less likely to resolve with relief
of the cause than PH commencing after the pulmonary
circulation has matured.
3
Remodeling and “reversibility” of increased
PVR with PVH
The fact that PVR decreases over a matter of months after
mitral valve intervention suggests that the decrease is partly
due to favorable remodeling. Unfortunately, there is little
documentation of what actually happens with the decrease
inPVR, but one canspeculate:smoothmuscle hypertrophy/
hyperplasia presumably regresses, and edema in the vessel
walls is perhaps reduced. What happens to the intimal pro-
liferation is unclear. Intimal proliferation and ﬁbrosis do not
imply a ﬁxed increase in PVR with mitral stenosis,
50-52,54
even though such lesions often portend an unfavorable out-
come with shunting lesions.
68 T h i sm a yb em o s t l yam a t t e r
of degree: perhaps the fraction of the vascular bed occluded
by intima is smaller with PVH than other forms of PH; the
observation by Wagenvoort and Wagenvoort
50 that intimal
lesions are rarely occlusive with PVH is consistent with this.
Possibly the pattern of intimal proliferation is relevant. Us-
ing three-dimensional reconstruction, Yaginuma and co-
workers
69 found that, with cardiac shunting malformations,
intimal occlusion mostly affected small (100–150-μmd i am e -
ter) PAs at branch points or at the terminal end of very small
vessels. If, with PVH, intimal proliferation is mostly con-
ﬁned to arteries with somewhat larger diameters, it would
have less impact on the cross-section area of the vascular
bed, and favorable remodeling would therefore be mostly
due to reduction of smooth muscle mass.
One investigator’s analysis of data sets of hemodynamic
information obtained at cardiac catheterization suggests
that the hydrodynamics of PVH-PH differ from those of
PH without venous hypertension: with PH, mean PVR
and PA compliance are consistently inversely related when
LAP is normal, but with elevated LAP (>20 mmHg), com-
pliance decreases as PVR increases.
70 The reasons for this
are unclear, but it could be that PVH stimulates changes in
the geometry and mechanical properties of small pulmo-
nary vessels different from those that occur in other forms
of PH. The fact that plexiform lesions are seldom seen
with PVH, even with long-standing and severe PH, also
suggests that the architecture of vascular disease with PVH
is, at least in some ways, distinct from that of some other
forms of PH. Future investigations will hopefully better
deﬁne the microanatomic and biological characteristics
that distinguish PVH-related PH from other varieties of
the condition.
WALL STRESS AND PVH-PH
Many molecules and pathways have been identiﬁed as be-
ingpossiblyrelevant to pulmonary vascularremodelingand
vasoconstriction, but it is still unknown for any type of PH
to what extent these pathways are actually relevant, how
they interact with other pathways, and which biological
components have yet to be uncovered.
71 Abnormalities ob-
served with other forms of PH have been demonstrated
with PVH-PH (e.g., increased circulating endothelin-1 lev-
els), but the meaning of this is unclear. For example, the
fact that plasma endothelin-1 levels correlate with PAP in
heart failure
72doesnot establisharolefor thepeptideinthe
genesis of the PH. I will thus refrain from speculation re-
garding the usual PH molecular suspects, recognizing that
some pathways that are relevant in other forms of PH will
ultimately be shown to be involved in PVH-PH. Focus will
be directed on the hypothesis that the fundamental cause of
PVH-increased PVR is increased intravascular pressure,
leading to increased wall stress and/or stretching of PAs
and veins. This hypothesis has intuitive appeal, given that
increased intravascular pressure is the obvious consistent
consequence of PVH. The fact that relief of PVH usually
substantially reduces PVR also powerfully suggests that in-
creased intravascular pressure plays a signal role. Finally,
increased wall stress causes pathologic remodeling in
systemicarteries.
73-77
Note that intravascular pressure is not the only plausible
relevant mechanical force. The cross-sectional area of the
pulmonary vascular bed is presumably reduced with PVH-
increased PVR, implying (absent lower ﬂow) that shear
stress is increased. A general discussion of the effect of
shear on vascular biology is left to previous reviews,
78,79 al-
though attention will be given to a speciﬁc way that endothe-
lial shear may modulate the effect of increased wall stress.
There are at least three ways that increased pressure
in pulmonary blood vessels may increase PVR: myogenic
Pulmonary Circulation Volume 4 Number 4 December 2014 | 585vasoconstriction, pathological remodeling induced by in-
creased wall stress, and vasoconstriction induced by disten-
tion of large (main and proximal branch) PAs.
Myogenic vasoconstriction
Contractile activation of smooth muscle can be elicited by
increased stretch or tension in smooth muscle itself (al-
though it is modulated by endothelial cells) and plays an
important role in adjusting tone in at least some systemic
vascular beds.
80 There is ample reason to think that myo-
genic constriction can also occur in the lung: ﬁrst, stretch
or increased intraluminal pressure stimulates constriction
in segments of small PAs in vitro in multiple species,
81-85
and second, myogenic tone,atphysiologically relevant pres-
sures, has been demonstrated in the in situ lung of the
ovine fetus
86,87 and (pace assertions that this response is
lacking in normoxic mature animals
88) mature feline, ca-
nine, and ovine lungs.
42,89,90
An apparent objection to the pulmonary myogenic tone
hypothesis is the observed effect of exercise on PVR (it gen-
erally decreases it). Passive distention of small pulmonary
vessels at least partly accounts for the ﬂow-mediated de-
crease in PVR,
91 which seems inconsistent with the notion
of distention-mediated vasoconstriction. Storme and col-
leagues,
86 however, showed that, in the fetal lung, vaso-
constriction with ductal compression occurs only when
endothelial release of NO is blocked using NO synthase in-
hibition. They surmise that increased PA ﬂow with ductal
constriction causes endothelial release of NO, which pre-
vents smooth muscle activation, but when NO production is
inhibited, myogenic contraction is made manifest. Inhibi-
tion of myogenic contraction by ﬂow-stimulated NO release
could also occur with exercise,
92-94 explaining why disten-
tion of small PAs in this setting does not cause vasoconstric-
tion. In fact, the magnitude of endothelial modulation of
myogenic tone could at least partially account for variability
in PVR with PVH: Cooper and colleagues,
95 using N
G-
monomethyl-l-arginine to inhibit NO production, found
that, in adults with PH due to left ventricular noncompli-
ance, those with increased PVR had less baseline NO modu-
lation of PVR than patients with normal PVR. Whether this
is due to a limited capacity to generate NO or reduced pro-
duction for other reasons is unclear, but some patients with
PVH and increased PVR show substantial vasodilation with
acetylcholine infusion,
28,96 indicating that the endothelium
can have the capacity to produce NO but not generate it
maximally at baseline.
The myogenic tone hypothesis as an explanation for
PVH-related pulmonary vasoconstriction is currently mostly
that. There is still much to be learned about this phenome-
n o ni nt h el u n g .T ow h a te x t e n td o e si to c c u ri nh u m a n s ?I s
the magnitude of stretch caused by PVH-related increased
intraluminal pressure enough to stimulate myogenic con-
traction? Does it operate in the setting of chronically in-
creased intraluminal pressure? What non-smooth-muscle
cells and circulating or paracrine factors modulate the re-
sponse? Why do vasodilators only partly abolish increased
PVR with PVH and have no effect at all in some people?
Presuming myogenic tone is present and important in the
pulmonary circulation, is its mechanism sufﬁciently distinct
from that in systemic vessels that speciﬁc inhibition is a
possibility? Deﬁnitive conﬁrmation and characterization of
therole—andpossiblepharmacologicmodulation—ofmyo-
genic tone in PVH-PH will likely have to wait until selective
antagonistsforstretch-operatedchannelsand/orothercom-
ponents of the machinery of mechanically induced contrac-
tileactivationaredeveloped.
74,80
Alas, our fragmentary understanding of the molecular
mechanisms underlying the SMC stretch response seri-
ously constrains our ability to better characterize it in vivo
and manipulate it. Although investigators have learned a
lot about how mechanical forces are translated into biologi-
cal effect in SMC, a granular picture of the mechanisms
involved has yet to evolve. Transmembrane Ca
2+ ﬂux and
Ca
2+ releasefrom intracellular stores are keyearlyevents,but
exactly what mediates them is unclear. Stretch-responsive
elements in vascular SMC likely include ion channels, pos-
sibly including nonselective cation channels dubbed
stretch-activated channels (SACs) and multiple others (e.g.,
transmembrane receptor potential channels, BKCa chan-
nels, Kv channels, ENaC channels, and ClCa channels).
Some of these channels (e.g., SACs) increase [Ca
2+]v i a
membrane depolarization, whereas others modulate the in-
crease (e.g., BKCa channels). Alternatively, or in addition to
stretch-sensitive channels, cytoskeletal elements may serve
as mechanotransducers. For example, integrins, binding to
matrix proteins and cytoskeletal elements, induce changes
in the latter and have received much attention as putative
primary mechanotransducers. Multiple other structures or
molecules (e.g., caveolae and G proteins) may also serve as
mechanosensors in SMC.
76,80,97,98 Considerably more work
remains before we learn enough to allow the stretch re-
sponse to be selectively manipulated toward investigative
and therapeutic ends.
Pathological remodeling induced by increased
wall stress
Pathological remodeling induced by increased wall stress
can occur either as a direct consequence of increased vas-
cular tone or as a reaction to increased stress per se. One
586 | Pulmonary venous hypertension and PH Kulikpossible explanation for increased vascular resistance in
systemic hypertension is that contraction of small arteries
becomes “entrenched.” With this “eutropic” remodeling,
the lumen of the arteries is reduced in diameter without
increasing smooth muscle mass.
99,100 In an analogous
way, might myogenic contraction directly lead to the
structural changes seen with PVH and other forms of
PH? Perhaps the ﬁrst question one might ask is whether
pathologic remodeling in the lung is eutrophic, or whether
there is increased smooth muscle mass in remodeled
small vessels? We are not aware of information for PVH-
PH (most reports describe medial hypertrophy but do not
comment on vessel diameter), but with a large ventricular
septal defect, the external diameter of small (generally
intraacinar) PAs is normal or reduced much more often
than it is dilated, and the luminal diameter is reduced by
virtue of increased medial thickness.
101-104 Likewise, in
multiple experimental models of increased pulmonary
blood ﬂow with or without increased PAP, small PAs are
usually of normal or reduced diameter.
105-107 Whether
smooth muscle mass is normal or increased cannot be
determined from the data presented, but reduced vessel
diameter (and thickened media) is consistent with eutropic
remodeling. Although such remodeling would not directly
account for dilation lesions (which are not seen with
PVH-PH but are seen with other forms of PH), increased
PAP due to narrowed resistance vessels could lead to other
microarchitectural abnormalities.
Intimal proliferation is a feature of pathological remod-
eling in some patients with PVH-PH, and there are at least
two ways that this might be linked with myogenic vasocon-
striction. First, reduced ﬂow in systemic arteries, or vascu-
lar grafts, can cause neointimal proliferation.
99,108 Because
the pulmonary microvascular bed branches dichotomously
(and also has lateral branches), distal constriction of the
small branches will reduce ﬂow in those vessels; reduced
ﬂow in these very small arteries could possibly stimulate
neointimal proliferation. The pattern of intimal hyperpla-
sia demonstrated by Yaginuma and colleagues
69 in pa-
tients with congenital cardiac shunting defects and PH—
that is, occlusion of very small branches arising from an
unaffected larger artery—is consistent with this notion.
Second, systemic veins and arteries subject to high
intraluminal pressure develop intimal hyperplasia. Al-
though vascular injury and inﬂammation may account
for some of this effect, stretch probably also causes neo-
intima independently of these factors.
77,109-111 By increas-
ing PAP via constriction of small PAs, myogenic con-
traction might thus serve as the inciting stimulus for
intimal hyperplasia of more proximal arteries. To what ex-
tent the biology of relatively large systemic veins and arter-
ies applies to very small PAs is unclear, but it is notewor-
thy that, in a murine model of veins subjected to high
pressure, neointimal formation is in part dependent upon
expression of early growth response factor-1,
77 a transcrip-
tion factor associated with intimal lesions in at least 2
forms of PH;
112,113 similar observations have been made
for tissue inhibitor of metalloprotinease-1.
111,114
Finally, because myogenic contraction involves trans-
membrane Ca
2+ ﬂux,
80,115,116 and SMC growth and mi-
gration require increased intracellular [Ca
2+],
117,118 these
cellular events related to contraction might simulta-
neously augment pathological remodeling stimulated by
other factors.
Whether or not myogenic contraction is an inciting
stimulus for pathological remodeling in the lung, multi-
ple studies of in vitro systemic and (to a much lesser
extent) PA SMC and vascular segments have shown that
stretch increases SMC growth and matrix protein syn-
thesis,
30,119-123 stimulates intimal hyperplasia,
77 and has
multiple other remodeling-relevant effects (e.g., apopto-
sis and migration).
73,74 Over the last 30 years, many
studies have been published regarding the impact of me-
chanical forces on many types of cells and tissues, and it
now is axiomatic that wall (and shear) stress are impor-
tant regulators of vascular architecture.
There is still much to be learned. (i) Most studies com-
pare stretched with unstretched cultured cells, but in
vivo, it is the magnitude of mechanical stimulus—not its
presence versus absence—that is relevant. If an SMC
subjected to a 5% periodic strain (due to pulsatile ex-
pansion of the artery) is subjected to an 8% strain due
to higher intraluminal pressure, how does it respond?
(ii) Stretched cultured cells are almost always attached to a
two-dimensional surface, but they behave differently when
embedded in a three-dimensional matrix, which better re-
ﬂects their in situ geometrical arrangement.
74 (iii) In ex-
periments using vessel segments, they are usually stati-
cally stretched,
30,121,122,124 whereas cyclical stretch pertains
in vivo. (iv) Cells from large, rather than resistance, arter-
ies are used, and the vast majority of experiments use
systemic SMC; there are few studies of PA SMC or vascu-
lar segments. Because at least some PA SMC characteris-
tics differ according to the size of the vessel,
125 experi-
ments using small (<300-μm diameter) vessels or cells
from them would be required to know how the body of
work noted above applies to the PAs that control PVR.
(v) Upon which cells does wall stress act, and how do they
modulate contractility and growth? Although most studies
have focused on SMC, cultured systemic endothelial cells
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angiotensin II and superoxide.
126 Adventitial cells could
also be involved.
More studies of the impact of mechanical forces on cel-
lular and molecular events in whole tissues and the in vivo
pulmonary circulation are needed, but this is challenging.
PVH is the only deﬁnable stimulus that increases PAP
without increased ﬂow, alveolar hypoxia, genetic modiﬁca-
tion, toxins, or other pharmacological agents, but these
studies are technically more difﬁcult than other models of
PH. Few have addressed cellular and molecular mecha-
nisms involved in pathologically remodeling.
127-129 Ulti-
mately, however, a deeper comprehension of the mecha-
nisms of all types of PH must include a more precise
reckoning of how increased wall stress regulates vascular
biology.
Vasoconstriction induced by distention of large
(main and proximal branch) PAs
Multiple investigators have found that distention of the
main or proximal branch PAs acutely increases PVR, pre-
sumably via neutrally mediated constriction of resistance
vessels. These studies have used closed
130-136 and open-
chest
137,138 canine and ovine preparations, and there is one
report involving human infants undergoing cardiac cathe-
terization.
139 The magnitude of PAP increase is variable,
generally being modest but sometimes considerable. In-
ﬁltration of the large PAs with xylocaine distal to the dis-
tended segment
130,133 and surgical disruption of the ad-
ventitia
134 reduce or abolish the vasoconstriction, as does
6-hydroxydopamine,
133,134 suggesting that nerves running
from large to resistance PAs mediate the vasoconstriction.
If so, the nerves are apparently not catecholaminergic, be-
cause alpha receptor blockade does not abolish the re-
sponse.
131,133 Ganglionic blocking agents, sympathectomy,
and vagotomy do not abolish the vasoconstriction.
130,131
Not all investigators have found large PA distention to
cause distal vasoconstriction.
140-142 Indeed, one investiga-
tor responsible for multiple articles describing this vaso-
constrictor response (Juratsch) subsequently collaborated
on a study suggesting that the technique used by him (in-
ﬂation of a “Laks” catheter in the main PA to cause disten-
tion) may occlude a branch PA and hence increase PAP
due to increased ﬂow rather than vasoconstriction.
141
However, given that multiple investigators have demon-
strated distention-mediated vasoconstriction using multi-
ple techniques, it is hard to discount the possibility that
this “reﬂex” is an important feature of the lung’s circula-
tion. That said, the magnitude of distention required to
cause vasoconstriction is rarely quantiﬁed, and it is un-
known whether the surely gradual increase in PA diameter
accompanying the gradual onset of PH with PVH would
be sufﬁcient to stimulate much, if any, vasoconstriction. It
seems more likely that the stretch vasoconstrictor response
mediates or augments acute increases in PAP occasioned
by exercise or other stimuli in people with preexisting PH
rather than being an important factor in the genesis of
PH.
TREATING PVH-PH
Over half a century ago, cardiologists caring for and per-
forming hemodynamic studies involving people with mi-
tral stenosis appreciated that LA pressure can exceed
serum oncotic pressure, putting these patients at risk for
pulmonary edema. They suggested that increased resis-
tance to ﬂow through precapillary arteries may be protec-
tive, shielding capillaries from high pressure at the cost of
limiting cardiac output.
1,28 Paul Wood, the acerbic “gale
force wind of British cardiology,”
143,144 concluded that pul-
monary edema, congestive hemoptysis, and paroxysmal
orthopnea were less common in patients with mitral ste-
nosis and high PVR than in those with lower resistance.
34
Reducing precapillary constriction with vasodilators can in-
deed provoke pulmonary edema in some patients with
PVH.
8-11 On the other hand, at least one clinician, practic-
ing early in the days of mitral valve palliation, concluded
that those with mitral valve disease and high PAP had
increased risk of dyspnea attacks relative to those with
lower pressure,
60 and it is certainly plausible that, for some
patients, limitation of right ventricular output due to PH,
not lung water, is what causes most symptoms. Pharmaco-
logic modulation of the body’s (apparently excessive) re-
sponse to myocardial dysfunction (diuretics, angiotensin
converting enzyme inhibitors, and beta blockers) is foun-
dation therapy for congestive LV failure, and one could
argue analogously that carefully monitored use of agents
aimed at reducing excessively increased PVR could be use-
ful for some patients with PVH.
However, deﬁning what role PH-targeted therapy may
play in the context of PVH-PH is complicated by the cur-
rent demographic characteristics associated with this de-
rangement. Because mitral valve disease is now largely
susceptible to mechanical alleviation, PVH (at least in
adults) is mostly a consequence of LV dysfunction. Clinical
trials of PH-targeted therapy have therefore involved pa-
tients with an additional and often severe physiological lia-
bility related to the left heart. So far, at least, there is little
to suggest that vasodilators are helpful in patients with LV
dysfunction and PVH-PH, and some appear to be harmful.
As has been well-reviewed by Guazzi and Arena,
21 trials of
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tients with congestive heart failure have not yielded signiﬁ-
cant clinical or hemodynamic beneﬁt or have actually
exacerbated heart failure or hastened death. Calcium chan-
nel blockers have received little attention in this regard,
perhaps because of early studies showing them, with con-
gestive heart failure, to not confer survival beneﬁt and
safety concerns regarding their use in this context.
145,146 A
recently reported 16-week randomized, placebo-controlled
trial of riociguat in 201 patients with heart failure with
LV systolic dysfunction and PH (baseline mean PAP,
∼40 mmHg) found that this guanylate cyclase stimula-
tor had no signiﬁcant effect, relative to placebo, on the
primary end point of PAP (although cardiac output was
increased, and there was improvement in a health-related
quality of life index).
147
The story may be different for sildenaﬁl. Multiple small
studies of patients with heart failure and systolic dysfunc-
tion suggest that this medication improves pulmonary vas-
cular hemodynamics and sometimes functional status
(reviewed in Guazzi and Arena,
21 Cooper et al.,
148 and
Redﬁeld et al.
149). For example, Lewis and colleagues,
150 in
a randomized 12-week placebo-controlled trial, found that
sildenaﬁl decreased PVR, increased peak oxygen consump-
tion with exercise, and had other salutary clinical effects in
patients with systolic heart failure and PH. More informa-
tion is pending: the Sildenaﬁl in Heart Failure (SilHF)
trial, a multicenter, randomized, placebo-controlled clinical
trial of sildenaﬁl for patients with heart failure and systolic
LV dysfunction, is enrolling patients (October 2014).
148
In this 6-month trial, inclusion criteria include (among
others) a systolic PAP >40 mmHg (by echocardiography),
and the co-primary end points are patient global assess-
ment and 6-minute walk test.
On the other hand, two studies involving patients with
heart failure but preserved LV systolic function had dispa-
rate ﬁndings. Guazzi et al.
151 reported that sildenaﬁl sig-
niﬁcantly improved LV compliance and pulmonary he-
modynamics after 6 and 12 months. (The patients had
baseline mean PAP of ∼38 mmHg and PVR of ∼3.6 Wood
units.) However, the much larger RELAX trial demonstrated
no difference in peak VO2, 6-minute walk distance, or mean
clinical status rank score.
149 (The median systolic PAP by
echocardiography was 41 mmHg, considerably lower than
in the Guazzi trial, assuming that the noninvasive estimate
wasaccurate.)
Lacking clear beneﬁt, and with evidence of unfavorable
effects with some agents, routine use of targeted PH ther-
apy to treat PVH-PH is currently discouraged.
21,43,147,152
However, the question of whether pharmacologic therapy
could be beneﬁcial is a complex one and is not fully an-
swered by existing studies. It is perhaps useful to specu-
late on possible reasons why these medications have not
appeared to be helpful in the context of PVH-PH, despite
their utility in class 1 PH.
The drugs tested are ineffective in reducing PVR in PVH-
PH. Although this is likely true for some patients and
some drugs (e.g., riociguat), studies have shown that epo-
prostanol and sildenaﬁl effected at least as much reduction
in PVR in patients with heart failure as with idiopathic
pulmonary arterial hypertension (PAH).
150,151,153,154 The
fact that many patients with PH due to mitral valve disease
are “reactive” when tested with acute vasodilators also sug-
gests that, as a group, patients with PVH-PH should be at
least as likely to reduce PVR with chronic vasodilator ther-
apy as other patients with PH.
Unfavorable effects of the medications may be more impor-
tant than any hemodynamic beneﬁt. Increased lung water
is an obvious possible pernicious adverse effect, but there
could be any number of others, some known (i.e., ﬂuid
retention with endothelin receptor antagonists
155) and
others not yet identiﬁed. The Flolan International Ran-
domized Survival Trial trial, in which epoprostanol was
given to patients with LV dysfunction, is illustrative.
153
Both PAP and PVR were signiﬁcantly reduced, but the
study was halted early because of increased mortality
among treated subjects.
In patients with left heart failure, the physiological liabil-
ity related to LV dysfunction overwhelms that contributed by
PH. This seems likely to be the case when PAP is only
modestly elevated and right ventricular (RV) function is
adequate, and it could be true even with markedly elevated
PAP and severe LV dysfunction. Janicki et al.
156 found that
patients with pulmonary vascular disease were able to gen-
erate similar cardiac outputs with exercise as patients with
heart failure despite having considerably higher PAP, sug-
gesting that LV rather than RV function can be rate-
limiting in patients with LV failure and PH. Also, consider
that, even when targeted agents are used for patients with
PH and normal LV function (e.g., idiopathic PAH), their
effect on hemodynamic parameters and exercise capacity
is usually quite modest.
154 With severe LV systolic or dia-
stolic dysfunction, the LV may not be up to increasing its
output or reserve on account of a small increment in RV
performance.
Also, surely patients in any clinical trial who have little
elevation in PVR (especially with good RV function) have
much less, if anything, to gain from a reduction in that
variable compared with those patients with markedly ele-
vated PAP. Data from the trials noted above are consistent
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150 found that the change in
oxygen consumption with sildenaﬁl correlated with base-
line PVR—those with the highest pretreatment PVR had
the greatest increase in oxygen consumption with the
drug. In the Guazzi trial of sildenaﬁl with left heart fail-
ure,
151 the absolute decrease in PVR was (not surprisingly)
greatest in those with the highest baseline resistance. With
a few exceptions, clinical trials of pulmonary vasodilators
with left heart failure have not speciﬁed a minimum PAP
for inclusion or required only modest elevation, meaning
that, a priori, some fraction of subjects stood relatively little
to gain from a reduction in PVR. In fact, the difference in
ﬁndings between the RELAX and Guazzi sildenaﬁl trials
might, at least in part, relate to the fact that patients likely
had higher PAP (and more RV dysfunction) in the latter
trial.
149 The greater the percentage of patients with rela-
tively low PAP, the less likely that beneﬁt will be demon-
strated, even if some people with higher pressure have
signiﬁcant improvement.
Uncovering what, if any, role targeted PH pulmonary
therapy can play in people with PVH may therefore re-
quire clinical trials with enrollment limited to patients
with substantial PH (and perhaps RV dysfunction); alter-
natively, a subanalysis of outcomes among patients with
high PAP could be performed for large studies that con-
tain subjects with a range of PAP, assuming a sufﬁcient
number of patients. However, this poses practical prob-
lems. First, accurate determination of baseline pulmonary
vascular hemodynamics, given the limitations of echocar-
diography in accurately estimating PAP,
157 requires car-
diac catheterization, with the attendant expense and lo-
gistical complications. Second, enrollment of an adequate
number of subjects is more challenging if entry criteria are
more stringent and subjects need to consent to invasive
studies. Alternatively, n-of-1-like trials, in which a smaller
number of patients are more intensively monitored,
158
may yield generalizable information and be a means of
tailoring therapy to individual patients. Echocardiographic
screening (for PAP and RV and LV function) and clinical
characteristics could identify patients most likely to beneﬁt
from targeted PH therapy, and these people could be care-
fully evaluated for clinically meaningful improvement with
therapy. The medication would be discontinued absent
positive effect; reevaluation after being switched to placebo
could be undertaken for those who appeared to derive ben-
eﬁt. Although expensive and cumbersome, this sort of ap-
proach may be a way to rationally use agents that, while
showing sufﬁcient promise (e.g., sildenaﬁl) in small trials,
do not prove helpful when applied to a mixed (in terms of
PAP/PVR and RV function) population of patients. Alter-
natively (or additionally), the response of the pulmonary
circulation to exercise may better stratify patients relative
to the likelihood of a favorable response to targeted ther-
apy.
159
SUMMARY
Increased PVR due to PVH is a clear demonstration of
the effect of increased pressure per se on pulmonary vas-
cular tone and structure and is therefore of special inter-
est: the impact of any process that increases PAP (e.g.,
hypoxia, toxins, and genetic causes) may be magniﬁed by
the inherent tendency for PH to beget more PH. Even
were the mechanisms involved in the genesis of, for ex-
ample, idiopathic PAH to be distinct from those operative
in PVH-PH, understanding the latter could lead to thera-
pies to ameliorate the effects of the former. PVH-PH con-
ﬁrms the huge variability in the pulmonary circulation’s
response to vasoconstrictive/pathological remodeling stim-
uli and offers up a relatively clean model to investigate the
biology of this variability. It also shows that, more palpably
than in any other form of PH, even long-standing and
severely increased PVR can abate with elimination of the
inciting stimulus. We do not know what fraction of this
resolution is attributable to release of vasoconstriction, re-
duction of medial hypertrophy with or without intimal hy-
perplasia, or other structural vascular changes, but this
favorable physiological/structural remodeling might serve
as a paradigm for pulmonary vascular healing with other
forms of PH.
We need much better characterization of the molecular
mechanisms of stretch/tension transduction on SMC, in-
cluding delineation of any differences speciﬁc to pulmo-
nary blood vessels. This may lead to means of interfering
with mechanically stimulated contraction and remodeling
in the pulmonary circulation, which would be invaluable
for better deﬁning the role that increased pressure plays,
and to developing new types of therapy for all forms of
PH.
Despite its capacity for reversal, PVH-PH is an impor-
tant clinical problem, especially because LV diastolic dys-
function lacks deﬁnitive therapy. Clinical studies thus far
mostly suggest that currently available targeted PH ther-
apy is not useful—or worse—for the general population of
patients with PVH related to left heart dysfunction. How-
ever, there are a few reports suggesting that a subset of
patients may beneﬁt from such therapy, and the question
of whether current or future medications used to alleviate
other forms of PH can be safe and useful in this context
still hangs ﬁre. It may be that a different way of answer-
ing this question is needed, in which patients whose pul-
590 | Pulmonary venous hypertension and PH Kulikmonary vascular phenotype drives their physiology as
much as their left ventricular phenotype are treated and
evaluated.
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